Optimal bone health management strategies in patients with prostate cancer

Indian Journal of Urology

Volumn 29, Issue 2, 2013, Pages 89-99

  Prakash, Gagan ^a   Gautam, Gagan ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b MEDANTA THE MEDICITY   (India)

Author keywords

Bisphosphonates; Bone metastasis; Osteoclasts; Prostate cancer; Skeletal related events; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ATRASENTAN; COLECALCIFEROL; CREATININE; DASATINIB; DENOSUMAB; PLACEBO; PROTEIN TYROSINE KINASE; RADIUM CHLORIDE RA 223; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SAMARIUM 153; STRONTIUM 89; TOREMIFENE; ZIBOTENTAN; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ANDROGEN DEPRIVATION THERAPY; BONE HEALTH; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HEALTH; HEALTH CARE MANAGEMENT; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NOMOGRAM; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PROSTATE CANCER; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 84880316755     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.114024     Document Type: Review

References (74)

1. Smith MR, Brown GA, Saad F. New opportunities in the management of prostate cancer-related bone complications. Urologic Oncology: Seminars and Original Investigations. 2009;27:S1-20
2. Pradhan M, Mandhani A, Chipde S, Kumar J, Ansari MS, Srivastava A, et al. Bone mineral densitometry at the time of instituting Androgen Deprivation Therapy in metastatic prostate cancer: Does practice pattern match the guidelines? Indian J Urol 2012;S72
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
4. Clarke NW, McClure J, George NJ. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993;24:286-90
5. Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004;172:2137-44
6. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;148:680-4
7. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897-903
8. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer 2004;100:892-9
9. Kiralti BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127-32
10. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, et al. Incidence of skeletal complications in patients with bone metastaticprostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164:1248-53
11. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-22
12. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88:2952-60
13. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999;45:1359-68
14. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942-53
15. Briganti N, Passoni M, Ferrari, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: External validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010;57:551-8
16. Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, et al. Whole body MR imaging for detection of bone metastases in children and young adults: Comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-36
17. Thurairaja R, McFarlane J, Traill Z, Persad R. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int. 2004;94:268-71
18. Venkitaraman R, Sohaib AG, Cook G. MRI or bone scan or both for staging of prostate cancer? J Clin Oncol 2007;25:5837-8
19. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42:1800-4
20. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-Fluoride PET/CT. J Nucl Med 2006;47:287-97
21. Frank JA, Ling A, Patronas NJ, Carrasquillo JA, Horvath K, Hickey AM, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol 1990;155:1043-8
22. Kattapuram SV, Khurana JS, Scott JA, El-Khoury GY. Negative scintigraphy with positive magnetic resonance imaging in bone metastases. Skeletal Radiol 1990;19:113-6
23. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vandeberg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005;65:178-87
24. Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d'Othée BJ, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: Diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007;25:3281-7
25. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, D. C.: National Osteoporosis Foundation; 2003
26. Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003;170:S59-63
27. Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E. Bone fragility in men-where are we? Osteoporos Int 2006;17:1577-83
28. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int 2005;16:1330-8
29. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-94
30. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737-42
31. Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, et al. A meta-analysis of milk intake and fracture risk: Low utility for case finding. Osteoporos Int 2005;16:799-804
32. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, et al. A family history of fracture and fracture risk: A meta-analysis. Bone 2004;35:1029-37
33. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-9
34. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82
35. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: A meta-analysis. Osteoporos Int 2005;16:155-62
36. National Comprehensive Cancer Network: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer, 2010. Available from: http://www.nccn.org/professionals/physician-gls/PDF/prostate. pdf. [Last accessed 2012 Aug 23]
37. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997;80:1652-60
38. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007;1117:209-57
39. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98:1735-44
40. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7
41. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
42. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009;10:872-6
43. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011;29:3705-14
44. Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 2009;104:1637-40
45. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36
46. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76
47. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
48. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bonemetastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-9
49. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-22
50. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
51. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial. J Urol 2009;182:509-15; discussion 515-6
52. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2011;379:39-46
53. FDA panel votes against Amgen's Xgeva for prostate cancer. Los Angeles Times on the web. Feb 8 2012.Aug 22 FDA Panel votes against Amgen's Xgeva for prostate cancer. LosAngeles Timesontheweb. Available from: http://articles. latimes.com/2012/feb/08/business/la-fi-amgen-20120208 [Last accesed on 2012 Aug 22]
54. Haddad P, Wong RK, Pond GR, Soban F, Williams D, McLean M, et al. Factors Influencing the use of single vs multiple fractions of palliative radiotheraphy for bone metastases: A 5-year review. Clin Oncol (R Coll Radiol) 2005;17:430-4
55. Agarawal JP, Swangsilpa T, vander Linden Y, Rades D, Jeremic B, Hoskin PJ. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol) 2006;18:747-60
56. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010;40:89-104
57. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001;357:336-41
58. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium153EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med 1993;34:1839-44
59. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 2009;27:3319-24
60. Doreen S.Bayer's investigational compound radium-223 chloride met its primary endpoint of significantly improving overall survival in a phase III trial in patients with castration-resistant prostate cancer that has spread to the bone.Bayer Health Care. Available from: http://press.healthcare.bayer.com/ en/press/news-details-page. php/14214/2011-0301 [Last accessed on 2012 Aug 23]
61. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841-6
62. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152-5
63. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010;184:1316-21
64. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84
65. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-42
66. Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007;99:765-76
67. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55
68. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9
69. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55:1112-23
70. Xia W, Unger P, Miller L, Nelson J, Gelman IH. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001;61:5644-51
71. Saad F, Lipton A. SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177-84
72. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421-8
73. Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC3 bone model. Mol Cancer Ther 2010;9:1629-37
74. Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F. SKI606 (Bosutiblocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther 2010;9:1147-57